106,800 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 106,800 shares of the company’s stock, valued at approximately $16,086,000.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at $47,000. J.Safra Asset Management Corp boosted its holdings in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the last quarter. Signaturefd LLC grew its position in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the period. Fidelis Capital Partners LLC purchased a new position in shares of TransMedics Group during the 1st quarter valued at about $35,000. Finally, Amalgamated Bank lifted its holdings in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after buying an additional 70 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Down 3.3 %

Shares of NASDAQ TMDX opened at $159.50 on Tuesday. The firm has a market cap of $5.25 billion, a price-to-earnings ratio of -469.12 and a beta of 1.99. The company’s 50-day simple moving average is $155.95 and its 200-day simple moving average is $130.14. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same period in the previous year, the firm posted ($0.03) EPS. TransMedics Group’s revenue was up 117.7% compared to the same quarter last year. Equities analysts predict that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total value of $652,785.80. Following the transaction, the insider now owns 8,893 shares in the company, valued at approximately $1,353,514.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total value of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares in the company, valued at $1,353,514.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total value of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,948,714.31. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,247 shares of company stock worth $9,650,880. 7.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TMDX. Stephens lifted their price target on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Needham & Company LLC assumed coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 target price for the company. Cantor Fitzgerald started coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price target on the stock. Oppenheimer upped their price objective on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Finally, TD Cowen increased their target price on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $171.44.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.